Bristol-Myers Squibb's price target was cut by Cantor Fitzgerald following clinical setbacks.
4 reports, 2 independent
Updated Tue 00:00
No new developments lately
- Reports
- 4
- Developments
- 2
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Bristol-Myers Squibb's price target was cut by Cantor Fitzgerald following clinical setbacks.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Bristol-Myers Squibb rating cut and restatements announced.1 source
Cantor Fitzgerald cut BMS price target due to clinical setbacks.1 source
Keep exploring
The entities involved
-
Bristol-Myers Squibb
American pharmaceutical company
-
Cantor Fitzgerald
American financial services company
Related events
- CMS introduced the Medicare drug price negotiation program, and companies are facing challenges regarding pricing and market access.
- Analyst provides a high price target for Viking Therapeutics stock.
- Market competition observed in the large-cap healthcare sector involving Bristol-Myers Squibb and Orion OYJ.
- Cantor Fitzgerald raised its price target and rating for Supernus Pharmaceuticals, Inc. on September 2, 2026, and the company filed a disclosure with the SEC.
- Cantor Fitzgerald began coverage and issued rating, and Morgan Stanley upgraded price objective and rating for Silence Therapeutics.
Coverage
Newest first; wire copies grouped- themarketsdaily.com
- Insider MonkeyCantor Fitzgerald Cuts Bristol-Myers (BMY) Price Target, Keeps Neutral Bristol-Myers Squibb Company (NYSE:BMY) is one of the 10 Best Affordable Stocks Under $50 to Buy. On August 13, Cantor Fitzgeral